Safety Problems Help AstraZeneca Win Suit Brought By Former Partner Verus
Executive Summary
AstraZeneca is in a strange position for a pharmaceutical company: It has benefited in court because of safety problems observed in one of its products
You may also be interested in...
Deals Of The Week: Merck/Portola, MedImmune/Catalyst, iZumi/Pierian ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com/.
Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug
Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.
From Verus to Meritage: A Biotech Prototype for Tough Economic Times
Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.